Skip to main content
SpringerLink
Log in

The alpha spending function approach to interim data analyses

  • Chapter
Recent Advances in Clinical Trial Design and Analysis

Part of the book series: Cancer Treatment and Research ((CTAR,volume 75))

Abstract

Over the past three decades, clinical trials have become one of the major standards for evaluating new therapies and interventions in medicine [1–3]. Numerous clinical trials have been conducted during this period across a wide variety of diseases, evaluating drugs, procedures, devices, and biologic materials. The fundamentals of the design, conduct, and analyses of clinical trials have been developed and refined during this period as well. One such fundamental is that clinical data should be carefully monitored during the course of the trial so that unexpected or unacceptable toxicity can be detected as soon as possible in order to minimize patient exposure; in addition, trials should not be continued longer than necessary to prove the benefits of the therapy or intervention under study, or to understand the trade-offs between the benefits and risks of the therapy. In order to accomplish this goal, the National Institutes of Health sponsored a committee in the 1960s to develop guidelines for the conduct of clinical trials. The chair of this committee was Dr. Bernard Greenberg from the University of North Carolina, and the report, which was issued in 1967, has become known as the Greenberg Report [4], although it was only recently published in the literature. This report endorses the concept of interim review of data by an independent Data and Safety Monitoring Board (DSMB), a committee that has no conflict of interest for the study. This typically means that committee members should not be investigators entering patients into the trial. The Coronary Drug Project (CDP) [5] was one of the first trials to implement the Greenberg model.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Friedman L, Furburg C, DeMets DL (1985). Fundamentals of Clinical Trials, 2nd edition. Littleton, MA: PSG.

    Google Scholar 

  2. Pocock SJ (1983). Clinical Trials: A Practical Approach. New York: Wiley.

    Google Scholar 

  3. Peto R, Pike MC, Armitage P, et al. (1976). Design and analysis of randomized clinical trials requiring prolonged observations of each patient. I. Introduction and design. Br J Cancer 34:585–612.

    Article  PubMed  CAS  Google Scholar 

  4. Heart Special Project Committee (1988). Organization, review and administration of cooperative studies (Greenberg Report): A report from the Heart Special Project Committee to the National Advisory Council, May 1967. Controlled Clin Trials 9:137–148.

    Article  Google Scholar 

  5. Coronary Drug Project Research Group (1981). Practical aspects of decision making in clinical trials: The Coronary Drug Project as a case study. Controlled Clin Trials 1:363–376.

    Article  Google Scholar 

  6. Beta-Blocker Heart Attack Trial Research Group (1982). A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results. JAMA 247: 1707–1714.

    Article  Google Scholar 

  7. Cardiac Arrhythmia Suppression Trial (CAST) Investigators (1989). Preliminary report: Effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 321(6):406–412.

    Article  Google Scholar 

  8. DeMets DL (1990). Data monitoring and sequential analysis-An academic perspective. J AIDS 3 (Suppl 2):S124–S133.

    Google Scholar 

  9. DeMets DL (1984). Stopping guidelines vs. stopping rules: A practitioner’s point of view. Comm Stat (A) 13(19):2395–2417.

    Article  Google Scholar 

  10. DeMets DL, Hardy R, Friedman LM, Lan KKG (1984). Statistical aspects of early termination in the Beta-Blocker Heart Attack Trial. Controlled Clin Trials 5:362–372.

    Article  Google Scholar 

  11. Pawitan Y, Hallstrom A (1990). Statistical interim monitoring of the cardiac arrhythmia suppression trial. Stat Med 9:1081–1090.

    Article  PubMed  CAS  Google Scholar 

  12. Fleming T, DeMets DL (1993). Monitoring of clinical trials: Issues and recommendations. Controlled Clin Trials 14:183–197.

    Article  PubMed  CAS  Google Scholar 

  13. Pocock SJ (1993). Statistical and ethical issues in monitoring clinical trials. Stat Med 12:1459–1469.

    Article  PubMed  CAS  Google Scholar 

  14. Pocock SJ (1992). When to stop a clinical trial. Br Med J 305:235–240.

    Article  CAS  Google Scholar 

  15. Emerson SS, Fleming TR (1990). Interim analyses in clinical trials. Oncology 4:126–133.

    PubMed  CAS  Google Scholar 

  16. Task Force of the Working Group on Arrhythmias of the European Society of Cardiology (in press). The early termination of clinical trials: Causes, consequences, and control-with special reference to trials in the field of arrhythmias and sudden death. Eur Heart J.

    Google Scholar 

  17. Lai TL (1984). Incorporating scientific, ethical and economic considerations into the design of clinical trials in pharmaceutical industry: A sequential approach. Comm Stat (A) 13: 2355–2368.

    Article  Google Scholar 

  18. Wald A (1947). Sequential Analysis. New York: Wiley.

    Google Scholar 

  19. Bross I (1952). Sequential medical plans. Biometrics 8:188–205.

    Article  Google Scholar 

  20. Anscombe FJ (1963). Sequential Medical Trials. J Am Stat Assoc 58:365–383.

    Article  Google Scholar 

  21. Armitage P (1975). Sequential Medical Trials, 2nd edition. New York: John Wiley & Sons.

    Google Scholar 

  22. Armitage P, McPherson CK, Rowe BC (1969). Repeated significance tests on accumulating data. J R Stat Soc A 132:235–244.

    Article  Google Scholar 

  23. Robbins H (1970). Statistical methods related to the law or iterated logarithm. Ann Math Stat 41:1397–1409.

    Article  Google Scholar 

  24. Meier P (1975). Statistics and medical examination. Biometrics 31:511–529.

    Article  PubMed  CAS  Google Scholar 

  25. Canner PL (1977). Monitoring treatment differences in long-term clinical trials. Biometrics 33:603–615.

    Article  PubMed  CAS  Google Scholar 

  26. Whitehead J (1991). The Design and Analysis of Sequential Clinical Trials, 2nd edition. Chichester: Ellis Horwood.

    Google Scholar 

  27. Haybittle JL (1971). Repeated assessment of results in clinical trials of cancer treatment. Br J Radiol 44:793–797.

    Article  PubMed  CAS  Google Scholar 

  28. Pocock SJ (1977). Group sequential methods in the design and analysis of clinical trials. Biometrika 64:191–199.

    Article  Google Scholar 

  29. O’Brien PC, Fleming TR (1979). A multiple testing procedure for clinical trials. Biometrics 35:549–556.

    Article  PubMed  Google Scholar 

  30. Lan KKG, DeMets DL (1983). Discrete sequential boundaries for clinical trials. Biometrika 70:659–663.

    Article  Google Scholar 

  31. DeMets DL (1987). Practical aspects in data monitoring: A brief review. Stat Med 6: 753–760.

    Article  Google Scholar 

  32. Jennison C, Turnbull BW (1990). Statistical approaches to interim monitoring of medical trials: A review and commentary. Stat Sci 5:299–317.

    Article  Google Scholar 

  33. DeMets DL, Lan KKG (in press). Interim analyses: The alpha spending function approach. Stat Med.

    Google Scholar 

  34. Lan KKG, DeMets DL, Halperin M (1984). More flexible sequential and non-sequential designs in long-term clinical trials. Comm Stat (A) 13(19):2339–2353.

    Google Scholar 

  35. Lan KKG, Zucker D (1993). Sequential monitoring of clinical trials: the role of information in Brownian motion. Stat Med 12:753–765.

    Article  PubMed  CAS  Google Scholar 

  36. Hwang IK, Shih WJ (1990). Group sequential designs using a family of type I error probability spending function. Stat Med 9:1439–1445.

    Article  PubMed  CAS  Google Scholar 

  37. Kim K, DeMets DL (1987). Design and analysis of group sequential tests based on the type I error spending rate function. Biometrika 74:149–154.

    Article  Google Scholar 

  38. DeMets DL, Ware JH (1982). Asymmetric group sequential boundaries for monitoring clinical trials. Biometrika 69:661–663.

    Article  Google Scholar 

  39. Emerson SS, Fleming TR (1989). Symmetric group sequential test designs. Biometrics 45:905–932.

    Article  PubMed  CAS  Google Scholar 

  40. Lan KKG, DeMets DL (1989). Group sequential procedures: calendar versus information time. Stat Med 8:1191–1198.

    Article  Google Scholar 

  41. Lan KKG, Reboussin DM, DeMets DL (in press). Information and information fractions for design and sequential monitoring of clinical trials. Comm Stat (A).

    Google Scholar 

  42. Lan KK, Wittes J (in press). Data monitoring in complex clinical trials: which treatment is better? J Stat Planning Inference.

    Google Scholar 

  43. Li Z, Geller NL (1991). On the choice of times for date analysis in group sequential trials. Biometrics 47:745–750.

    Article  PubMed  CAS  Google Scholar 

  44. Lan KKG, DeMets DL (1989). Changing frequency of interim analyses in sequential monitoring. Biometrics 45:1017–1020.

    Article  PubMed  CAS  Google Scholar 

  45. Proschan MA, Follman DA, Waclawiw MA (1992). Effects of assumption violations on type I error rate in group sequential monitoring. Biometrics 48:1131–1143.

    Article  Google Scholar 

  46. Kim K, DeMets DL (1992). Sample size determination for group sequential clinical trials with immediate response. Stat Med 11:1391–1399.

    Article  PubMed  CAS  Google Scholar 

  47. Fleming TR, Harrington DP (1991). Counting Processes and Survival Analysis. New York: Wiley.

    Google Scholar 

  48. Tarone R, Ware J (1978). On distribution free tests for equality of survival distributions. Biometrika 64:167–179.

    Google Scholar 

  49. Gail MH, DeMets DL, Slud EV (1992). Simulation studies on increments of the two-sample logrank score test for survival time data, with application to group sequential boundaries. In Survival Analysis, J Crowley, R Johnson (eds.), vol. 2. Hayward, CA: IMS Lecture Note Series.

    Google Scholar 

  50. Tsiatis AA (1982). Repeated significance testing for a general class of statistics used in censored survival analysis. J Am Stat Assoc 77:855–861.

    Article  Google Scholar 

  51. Slud E, Wei LJ (1982). Two-sample repeated significance tests based on the modified Wilcoxon statistic. J Am Stat Assoc 77:862–868.

    Article  Google Scholar 

  52. DeMets DL, Gail MH (1985). Use of logrank tests and group sequential methods at fixed calendar times. Biometrics 41:1039–1044.

    Article  Google Scholar 

  53. Lan KKG, Lachin J (1990). Implementation of group sequential logrank tests in a maximum duration trial. Biometrics 46:759–770.

    Article  PubMed  CAS  Google Scholar 

  54. Sellke T, Siegmund D (1983). Sequential analysis of the proportional hazards model. Biometrika 70:315–326.

    Article  Google Scholar 

  55. Kim K, Tsiatis AA (1990). Study duration for clinical trials with survival response and early stopping rule. Biometrics 46:81–92.

    Article  PubMed  CAS  Google Scholar 

  56. Kim K (1992). Study duration for group sequential clinical trials with censored survival data adjusting for stratification. Stat Med 11:1477–1488.

    Article  PubMed  CAS  Google Scholar 

  57. Lan KKG, Rosenberger WF, Lachin JM (1993). Use of spending functions for occasional or continuous monitoring of data in clinical trials. Stat Med 12:2214–2231.

    Google Scholar 

  58. Lee, JW (1994). Group sequential testing in clinical trials with multivariate observations: a review. Stat Med 13:101–111.

    Article  PubMed  CAS  Google Scholar 

  59. Laird NM, Ware JH (1983). Random effects models for longitudinal data. Biometrics 38:963–974.

    Article  Google Scholar 

  60. Lee JW, DeMets DL (1991). Sequential comparison of change with repeated measurement data. J Am Stat Assoc 86:757–762.

    Article  Google Scholar 

  61. Lee JW, DeMets DL (1992). Sequential rank tests with repeated measurements in clinical trials. J Am Stat Assoc 87:136–142.

    Article  Google Scholar 

  62. Wu MC, Lan KKG (1992). Sequential monitoring for comparison of changes in a response variable in clinical trials. Biometrics 48:765–779.

    Article  PubMed  CAS  Google Scholar 

  63. Wei LJ, Su JQ, Lachin JM (1990). Interim analyses with repeated measurements in a sequential clinical trial. Biometrika 77(2):359–364.

    Article  Google Scholar 

  64. Su JQ, Lachin J (1992). Group sequential distribution-free methods for the analysis of multivariate observations. Biometrics 48:1033–1042.

    Article  PubMed  CAS  Google Scholar 

  65. Smith E, Sempos CT, Smith PE, Gilligan C (1989). Calcium supplementation and bone loss in middle-aged women. Am J Clin 50:833–842.

    CAS  Google Scholar 

  66. Reboussin D, Lan KKG, DeMets DL (1992). Group sequential testing of longitudinal data. Technical Report #72, Department of Biostatistics, University of Wisconsin, Madison, WI.

    Google Scholar 

  67. Jennison C, Turnbull BW (1984). Repeated confidence intervals for group sequential trials. Controlled Clin Trials 5:33–45.

    Article  PubMed  CAS  Google Scholar 

  68. Jennison C, Turnbull BW (1989). Interim analyses: The repeated confidence interval approach. J R Stat Soc B 51:305–361.

    Google Scholar 

  69. DeMets DL, Lan KKG (1989). Discussion of: Interim analyses: The repeated confidence interval approach by C. Jennison and B.W. Turnbull. J R Stat Soc B 51:362.

    Google Scholar 

  70. Fleming TR, Watelet LF (1989). Approaches to monitoring clinical trial. J Natl Cancer Inst 81(3):188–193.

    Article  PubMed  CAS  Google Scholar 

  71. Fleming TR (1990). Evaluation of active control trials in AIDS. J AIDS 3 (Suppl):S82–S87.

    Google Scholar 

  72. Fleming TR (1978). Treatment evaluation in active control studies. Cancer Treat Rep 17(11):1061–1065.

    Google Scholar 

  73. Siegmund D (1978). Estimation following sequential tests. Biometrika 65:341–349.

    Google Scholar 

  74. Tsiatis AA, Rosner GL, Mehta CR (1984). Exact confidence intervals following a group sequential test. Biometrics 40:797–803.

    Article  PubMed  CAS  Google Scholar 

  75. Rosner GL, Tsiatis AA (1988). Exact confidence intervals following a group sequential trial: A comparison of methods. Biometrika 75:723–729.

    Article  Google Scholar 

  76. Kim K (1989). Point estimation following group sequential tests. Biometrics 45:613–617.

    Article  PubMed  CAS  Google Scholar 

  77. Kim K, DeMets DL (1987). Confidence intervals following group sequential tests in clinical trials. Biometrics 4:857–864.

    Article  Google Scholar 

  78. Whitehead J (1986). On the bias of maximum likelihood estimation following a sequential test. Biometrika 73:573–581.

    Article  Google Scholar 

  79. Emerson SS, Fleming TR (1990). Parameter estimation following group sequential hypothesis testing. Biometrika 77:875–892.

    Article  Google Scholar 

  80. Pocock SJ, Hughes MD (1989). Practical problems in interim analyses, with particular regard to estimation. Controlled Clin Trials 10:2094–2215.

    Article  Google Scholar 

  81. Chang MN, O’Brien PC (1986). Confidence intervals following group sequential tests. Controlled Clin Trials 7:18–26.

    Article  PubMed  CAS  Google Scholar 

  82. Whitehead J, Facey KM (1991). Analysis after a sequential trial: a comparison of orderings of the sample space. Presented at the Joint Society for Clinical Trials/International Society for Clinical Biostatistics, Brussels.

    Google Scholar 

  83. Hughes MD, Pocock SJ (1988). Stopping rules and estimation problems in clinical trials. Stat Med 7:1231–1241.

    Article  PubMed  CAS  Google Scholar 

  84. Whitehead J (1992). Overrunning and underrunning in sequential trials. Controlled Clin Trials 13:106–121.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. David L. DeMets
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gordon Lan
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Biomathematics, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Box 237, Houston, Texas, 77030, USA

    Peter F. Thall Ph.D.

Rights and permissions

Reprints and permissions

Copyright information

© 1995 Springer Science+Business Media New York

About this chapter

Cite this chapter

DeMets, D.L., Lan, G. (1995). The alpha spending function approach to interim data analyses. In: Thall, P.F. (eds) Recent Advances in Clinical Trial Design and Analysis. Cancer Treatment and Research, vol 75. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-2009-2_1

Download citation

  • DOI: https://doi.org/10.1007/978-1-4615-2009-2_1

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4613-5830-5

  • Online ISBN: 978-1-4615-2009-2

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation